News

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Ozempic and Wegovy, used for diabetes and weight loss, are now linked to a rare eye condition called NAION, or "eye stroke." ...
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...
The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...
A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...
Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...
Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.
The European Medicines Agency’s (EMA) safety committee, PRAC, said Friday that it has concluded that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), a rare eye condition that can lead to ...
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...